Trial ID	Intervention(s) and comparator(s)	Participants included in analysis (N)	Deaths (N)	Deaths (% of participants)	Participants with at least 1 adverse event (N)	Participants with at least 1 adverse event (%)	Participants with at least 1 severe/serious adverse event (N)	Participants with at least 1 severe/serious adverse event (%)
Ensor 2015	I: sucralose	207	‐	‐	‐	‐	‐	‐
	C: D‐tagatose	185	‐	‐	‐	‐	‐	‐
Barriocanal 2008	I: steviol glycoside	23	0	0	3	13.0	0	0
	C: placebo	23	0	0	5	21.7	0	0
Maki 2008	I: rebaudioside A	60	0	0	27	45.0	4	6.7
	C: placebo	62	0	0	23	37.1	3	4.8
Grotz 2003	I: sucralose	67	0	0	‐	‐	‐	‐
	C: placebo	69	0	0	‐	‐	‐	‐
Colagiuri 1989	I: aspartame	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Cooper 1988	I: saccharin and starch	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Chantelau 1985	I: sodium‐cyclamate	‐	‐	‐	‐	‐	‐	‐
	C: sucrose	‐	‐	‐	‐	‐	‐	‐
Nehrling 1985	I: aspartame	30	0	0	6	20	‐	‐
	C: placebo (cornstarch)	33	0	0	14	42.4	‐	‐
Stern 1976	I: aspartame	36	0	0	‐	‐	‐	‐
	C: placebo	33	0	0	‐	‐	‐	‐
‐: denotes not reported C: comparator; I: intervention; N: number of participants.